article thumbnail

Artificial pancreas will be piloted in 1,000 diabetics, says NHS CEO

pharmaphorum

NHS England will provide artificial pancreas devices to 1,000 type 1 diabetes patients as part of a pilot study of the technology, according to chief executive Sir Simon Stevens. Medtronic meanwhile has developed a closed-loop system – the MiniMed 640G – which was launched in the UK in 2015 for use alongside a CGM. Sir Simon Stevens.

Diabetes 131
article thumbnail

Opinion: Market share isn’t the only metric for biosimilars’ success

STAT

the first biosimilar was launched in September 2015. These 22 products compete in nine molecule classes across oncology, rheumatology, diabetes care, and now ophthalmology. In the U.S., As I write this, there are 38 FDA-approved biosimilars ; 22 of them are commercially available. According to the most recent “U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

China poised to lead the way with world’s first oral insulin for type 2 diabetes: GlobalData

Express Pharma

Hefei Tianhui Biotechnology (HTIT) has recently submitted a marketing authorisation application (MAA) in China for the world’s first oral insulin for type 2 diabetes (T2D). The number of diagnosed prevalent cases of type 2 diabetes in China is estimated to grow at a CAGR of 2.21 per cent from 57.4 million in 2022 to 63.3

article thumbnail

Sosei nets $10m Pfizer milestone as diabetes/obesity drug starts phase 2

pharmaphorum

Sosei Heptares’ longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established rivals from Novo Nordisk and Eli Lilly. The post Sosei nets $10m Pfizer milestone as diabetes/obesity drug starts phase 2 appeared first on.

article thumbnail

Living the life of a type 2 diabetes patient for a day

pharmaphorum

Mark Doyle, co-founder of The Method and creator of the A Life in a Day programme, tells us about the immersive experience he and his team created that allows anyone to live the life of a type 2 diabetes patient for 24 hours. Therefore, Doyle and his team created The Life in a Day immersive experience for type 2 diabetes.

article thumbnail

The US FDA Approves Boehringer Ingelheim’s Jardiance and Synjardy for the Treatment of Type 2 Diabetes

PharmaShots

Jardiance & Synjardy was approved in the US in 2014 & 2015, respectively. Ref: PR Newswire | Image: Boehringer Ingelheim Related News:- Eli Lilly Reports the US FDA’s Acceptance of sNDA for Jardiance to Treat Type 2 Diabetes PharmaShots! 52 patients had an average 0.2% decrease in hemoglobin A1c over 0.7%

article thumbnail

MyMAAT

RX Note

However, starting in 2015, Professor Donald Morisky and her team started charging researchers or practitioners USD 1-1.50 2019 Development and validation of Malaysia Medication Adherence Assessment Tool (MyMAAT) for diabetic patients, 2020 Paper that helped form basis of pricy research tool retracted, 2023 per test for copyright.